|
Top 10 Opportunities in Translational Cancer Medicine:
1. Combination Therapies
2. New Targets
3. Molecular Diagnostics
4. Companion Diagnostics
5. Better in vitro Models
6. Better in vivo Models
7. Biomarkers to Predict Drug Response
8. Cancer Biologics
9. Phase 0 Clinical Trials
10. Translational Imaging
|
|
Additional Coverage:
- Case Studies in Oncology Drug Development
- Cancer Biomarkers
- Translation from In-House Development to Clinical Laboratory
- Circulating Tumor Cell Assays
PRE-CONFERENCE SHORT COURSES:
- Novel Cancer Biomarkers
- Fit-for-Purpose Biomarker Assay Development and Validation
Distinguished Faculty:
J. Carl Barrett, Ph.D., Global Head, Oncology Biomarker and Imaging, Novartis Institutes for BioMedical Research, Inc.
Richard Bender, M.D., FACP, Chief Medical Officer, Agendia, Inc.
Josip Blonder, M.D., Senior Research Scientist, Laboratory of Proteomics and Analytical Technologies, SAIC-Frederick Inc., NCI-Frederick
Walter Carney, Ph.D., Head, Oncogene Science, Siemens Healthcare Diagnostics, Inc.
Daniel Chelsky, Ph.D., Chief Science Officer, Caprion Proteomics
James Christensen, Ph.D., Director, Translational Pharmacology, Pfizer Global Research and Development
Martin Fleisher, Ph.D., Chair, Dept. of Clinical Laboratories, Memorial Sloan-Kettering Cancer Center
Herbert A. Fritsche, Ph.D., Professor and Chief, Clinical Chemistry, The University of Texas M. D. Anderson Cancer Center
John A. Gilly, Ph.D., Deputy Director, Biopharmaceutical Development Program, SAIC-Frederick/NCI-Frederick
Garret Hampton, Senior Director, Biochemistry & Biomarker Development, Celgene Research San Diego
Joerg Heyer, Ph.D., Principal Scientist, Group Leader, Genetic Models, AVEO Pharmaceuticals, Inc.
J. Milburn Jessup, M.D., Chief, Diagnostics Evaluation Branch, Cancer Diagnosis Program, DCTD/National Cancer Institute
Francis Kalush, Ph.D., Network Leader, Diagnostics, Office of the Center Director, Center for Devices and Radiological Health, Food and Drug Administration
Mark R. Lackner, Ph.D., Scientist, Developmental Oncology Diagnostics, Genentech, Inc.
Theresa LaVallee, Ph.D., Director, Translational Sciences Oncology, MedImmune
Syed Mahmood, M.D., Associate Medical Director, Clinical Imaging Physician, Oncology Clinical Imaging, Novartis Pharmaceuticals Corporation
Anne-Marie Martin, Ph.D., Director, Oncology, MDC, GlaxoSmithKline
Glenn Merlino, Ph.D., Chief, Laboratory of Cancer Biology and Genetics; Chief, Cancer Modeling Section, National Cancer Institute
Søren Møller, Ph.D., Vice President, Research and Development, Exiqon A/S
Bryce P. Nelson, Ph.D., Vice President, Research and Development, Gentel Biosciences
Scott D. Patterson, Executive Director of Medical Sciences, Amgen, Inc.
Shannon Payne, Ph.D., Senior Scientist, Epigenomics, Inc.
Gregory J. Riggins, M.D., Ph.D., Irving J. Sherman M.D. Professor of Neurosurgery Research, Professor of Neurosurgery & Oncology, Department of Neurosurgery, Johns Hopkins University
Frank Richardson, D.V.M., Ph.D., Senior Director, Preclinical Safety Assessment and Molecular Markers, OSI Pharmaceuticals, Inc.
Anderson Ryan, Ph.D., Principle Translational Scientist, Cancer BioScience, AstraZeneca
Jeffrey Shuster, Ph.D., Director, Diagnostics Development, Metabolon, Inc.
Jon M. Wigginton, M.D., Group Medical Director, Discovery Medicine - Oncology, Bristol-Myers Squibb Co.
Lin Wu, Ph.D., Director, Genomics & Oncology, Roche Molecular Systems, Inc.